|By Marketwired .||
|May 29, 2014 07:30 AM EDT||
DURHAM, NC -- (Marketwired) -- 05/29/14 -- Heat Biologics, Inc. ("Heat Biologics", "Heat" or the "Company") (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of novel cancer immunotherapies, announced today that Jeff Wolf, Chief Executive Officer, will be presenting at the LD MICRO Fourth Invitational Conference at the Luxe Hotel in Los Angeles, California.
Heat's presentation is scheduled for Wednesday, June 4, 2014, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) in Track 4 of the conference and will include a review of the Company's lung and bladder cancer immunotherapy clinical development programs.
"We are honored to have Heat Biologics participating in our event this year," stated Chris Lahiji, President of LD MICRO.
Mr. Wolf will be available to participate in one-on-one meetings with investors attending the conference. One-on-one meetings for Heat Biologics can be scheduled through LD MICRO and at the conference. To learn more about LD MICRO and the LD MICRO Invitational, please visit www.ldmicro.com.
A live audio webcast of the Heat Biologics' presentation will be available on the Events page of the Investors section of the Company's website at www.heatbio.com. The webcast presentation will be archived on Heat's website for 90 days following the event.
About Heat Biologics, Inc.
Heat Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat will be entering Phase 2 trials with its HS-110 (Viagenpumatucel-L) against non-small cell lung cancer and is conducting Phase 1/2 clinical trials with its HS-410 (Vesigenurtacel-L) against bladder cancer. For more information, please visit www.heatbio.com.
About LD Micro
LD MICRO is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select micro-cap companies. The firm also hosts the LD MICRO Micro-Cap Growth Conference for investors in December of each year. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat's ImPACT Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed and Heat's ability to achieve its development and commercialization strategies, including its ability to obtain regulatory approvals. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.